Table 4.
Summary of pharmacokinetic parameters from the in vivo study of Cu B (mean ± standard deviation, n=5)
| Formulation | Cmax (μg/mL) | Tmax (h) | AUC0–24 (μg/mL/h) | F* |
|---|---|---|---|---|
| Cu B-PL/SDC-MMs | 9.69a±1.38 | 3.01±0.52 | 74.94a±6.03 | 3.73 |
| Dried powder containing Cu B-HPMC50 | 7.12a–c±1.23 | 3.03±0.41 | 44.02a,b±5.63 | 2.19 |
| Dried powder containing Cu B-TPGS20-HPMC30 | 8.30a,b±0.95 | 3.05±0.32 | 49.01a,b±4.72 | 2.43 |
| Control group | 3.55±0.71 | 3.03±0.46 | 20.11±3.22 |
Notes:
a
P<0.05 versus control group
b
P<0.05 versus Cu B-PL/SDC-MMs
c
P<0.05 compared with dried powder containing Cu B-TPGS20-HPMC30
*
relative bioavailability when compared with control group.
Abbreviations: AUC0–24, area under the curve during 24 hours; Cu B, cucurbitacin B; PL, phospholipid; HPMC, hydroxypropyl methyl cellulose; TPGS, alpha-D-tocopherol polyethylene glycol 1000 succinate; MMs, mixed micelles; SDC, sodium deoxycholate; Cmax, peak plasma concentration; Tmax, time taken to reach peak plasma concentration; h, hours.